Allarity Therapeutics, Inc. announced on November 18, 2026, that the United States Patent and Trademark Office has granted a U.S. patent covering specific treatment regimens for its drug candidate stenoparib, also known as 2X-121. The patent, assigned number 12,806,205, provides protection for the claimed methods into the year 2045.
The patent includes 36 allowed claims that cover the twice-daily oral administration of stenoparib. These claims encompass specified dose levels and treatment schedules relevant to the company's clinical development program. The patent also covers methods of treating advanced ovarian cancer and other solid tumors, including breast, colon, pancreatic, and prostate cancers. It specifically includes patients whose disease has not responded to prior therapies, such as other PARP inhibitors.
According to the filing, the patent complements Allarity’s previously issued U.S. patent covering its stenoparib-specific Drug Response Predictor (DRP) companion diagnostic. The company stated that the new patent strengthens the intellectual property foundation supporting the dosing strategy used in its ongoing Phase 2 program.
The patent arises from U.S. Patent Application No. 18/606,590. The company noted that the twice-daily dosing strategy is the regimen it intends to advance to pivotal trials. The press release also highlighted that the patent extends protection into 2045, which the company believes strengthens the foundation for continued investment in stenoparib and fuels future partnering discussions.